Loading...
•
Mar 31, 2020
Bruker Q1 2020 Earnings Report
Bruker's Q1 2020 financial performance was impacted by COVID-19, resulting in revenue decline.
Key Takeaways
Bruker reported a revenue decline of 8.1% year-over-year, with an organic revenue decline of 7.9%. GAAP EPS decreased to $0.07 from $0.20 in Q1 2019, and non-GAAP EPS decreased to $0.14 from $0.28 in Q1 2019. The company expects COVID-19 disruptions to negatively affect Q2 2020 financial results.
Q1 2020 revenue declined by 8.1% year-over-year.
Organic revenue declined by 7.9%.
GAAP EPS was $0.07, compared to $0.20 in Q1 2019.
Non-GAAP EPS was $0.14, compared to $0.28 in Q1 2019.
Bruker
Bruker
Forward Guidance
Bruker anticipates that the pandemic will have a more significant negative impact on the Company’s second quarter 2020 financial results. Fiscal Year 2020 (FY 2020) Guidance Remains Suspended
Positive Outlook
- Bruker is a healthy, essential company.
- Life science tools and diagnostics markets are quite resilient.
- Long-term funding trends in life science, biopharma and basic medical research, as well as in infectious disease diagnostics, are going to be strong as a result of the COVID-19 pandemic.
- Bruker is well positioned for a gradually improving business environment in the second half of 2020.
- Bruker continues to have a strong balance sheet and a very solid liquidity position.
Challenges Ahead
- COVID-19 disruption expected to negatively affect Q2 2020 financial results.
- First quarter 2020 results reflect the initial impact of the COVID-19 pandemic.
- Expect a more pronounced year-over-year revenue decline in the second quarter.
- Fiscal Year 2020 (FY 2020) Guidance Remains Suspended
- Uncertain business conditions created by COVID-19.